Roche immunotherapy combination increases lung cancer survival - study | RSS News Feed

Roche immunotherapy combination increases lung cancer survival - study - Latest News

RSS Feed for this news: Roche immunotherapy combination increases lung cancer survival - study

Roche immunotherapy combination increases lung cancer survival-study

(Reuters) - Roche’s immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage ... read more

3 Things In Biotech, May 26: Immunotherapy Strikes Lung Cancer Yet Again

AstraZeneca marks a new historic achievement in competitive lung cancer space ... their phase 3 study investigating the second-generation CD20 antibody ofatumumab in combination with bendamustine failed to improve progression-free survival for patients ... read more

Roche Reports Tecentriq/Avastin Lung Cancer Study Data

Roche’s RHHBY member ... The Tecentriq study is the first phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival for the first-line treatment of advanced lung cancer. The company expects to submit these ... read more

Looking for another news?


'We are going to have lung cancer patients living longer and better': A new kind of cancer treatment is about to change how we treat the disease

In data presented Monday at the American Association of Cancer Research's annual meeting, cancer-drug makers found that immunotherapy in combination with other drugs did a better job of treating lung ... Roche also shared its progression-free survival ... read more

Merck Wins Again; Esperion In Increments; Gilead As A Talent Farm

When it comes to the battle for the cancer ... chemotherapy increased both overall survival and PFS in the study. Investors will still need to see the data and compare it with a rival combination from Roche, but the news is good. The U.S. lung opportunity ... read more

Merck's Keytruda succeeds in late-stage lung cancer study

(Reuters) - Merck & Co on Wednesday said its cancer drug Keytruda helped extend survival and prevented disease progression when tested in a late-stage study in combination ... the only immunotherapy approved in the United States to treat lung cancer ... read more

Roche immunotherapy combination increases lung cancer survival-study

May 16 (Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late ... read more

Merck's cancer drug Keytruda notches another trial success

Keytruda, already approved for other types of cancer, is being studied in a late-stage trial as a first-line treatment, in combination ... in first-line non-small cell lung cancer in the United States. Keytruda is the only immunotherapy approved in the ... read more

Roche immunotherapy combination increases lung cancer survival - study

(Reuters) - Roche’s immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage ... read more


FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us